Serina Therapeutics Net Income vs. EBITDA

SER Stock   6.00  0.47  8.50%   
Based on Serina Therapeutics' profitability indicators, Serina Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Serina Therapeutics' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-14.8 M
Current Value
-15.5 M
Quarterly Volatility
3.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Serina Therapeutics' Price To Sales Ratio is relatively stable compared to the past year. As of 12/22/2024, EV To Sales is likely to grow to 161.02, while Sales General And Administrative To Revenue is likely to drop 1.20. As of 12/22/2024, Income Quality is likely to grow to 0.72, while Accumulated Other Comprehensive Income is likely to drop slightly above 116.6 K.
For Serina Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Serina Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Serina Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Serina Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Serina Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Serina Therapeutics. If investors know Serina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Serina Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
3.568
Earnings Share
0.14
Revenue Per Share
0.787
Quarterly Revenue Growth
6.286
Return On Assets
(0.45)
The market value of Serina Therapeutics is measured differently than its book value, which is the value of Serina that is recorded on the company's balance sheet. Investors also form their own opinion of Serina Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Serina Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Serina Therapeutics' market value can be influenced by many factors that don't directly affect Serina Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Serina Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Serina Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Serina Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Serina Therapeutics EBITDA vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Serina Therapeutics's current stock value. Our valuation model uses many indicators to compare Serina Therapeutics value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15BXPJBGSGMSMAHNUHGSDHCSER 0500M1B1.5B2B -100M-50M050M100M150M200M250M300M
Serina Therapeutics is currently regarded as top stock in net income category among its peers. It also is currently regarded as top stock in ebitda category among its peers . Serina Therapeutics reported last year Net Loss of (14.8 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Serina Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Serina EBITDA vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Serina Therapeutics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(14.8 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Serina Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(9.78 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Serina EBITDA Comparison

100%
Serina Therapeutics is currently under evaluation in ebitda category among its peers.

Serina Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Serina Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Serina Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Serina Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Serina Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income164.4 K116.6 K
Operating Income-10 M-10.5 M
Income Before Tax-14.8 M-15.6 M
Total Other Income Expense Net-4.9 M-4.6 M
Net Loss-14.8 M-15.5 M
Income Tax Expense-8 K-7.6 K
Net Interest Income-12.7 K-12.1 K
Interest Income1.6 K1.5 K
Net Loss-2.4 M-2.5 M
Net Loss(13.72)(13.03)
Income Quality 0.53  0.72 
Net Income Per E B T 0.90  0.78 

Serina Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Serina Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Serina Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Serina Therapeutics' important profitability drivers and their relationship over time.

Use Serina Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Serina Therapeutics Pair Trading

Serina Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Serina Therapeutics position

In addition to having Serina Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Copper Thematic Idea Now

Copper
Copper Theme
Companies involved in production of copper. The Copper theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Serina Stock Analysis

When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.

Trending Assets

GMS
GMS Inc
86.01  0.57  0.67 
MAHN
Mid Atlantic Home
0.0001  0.00  0.00 
BXP
Boston Properties
74.64  1.31  1.79 
JBGS
JBG SMITH Properties
15.36  0.22  1.45 
TBBB
BBB Foods
29.45  0.25  0.86 
SDHC
Smith Douglas Homes
27.82  -0.62  -2.18 
UHG
United Homes Group
4.18  0.02  0.48